Mergers & AcquisitionsMediumUpdated•Originally published 4 November 2026•Updated 4 November 2026•
1 min read
Rhythm Pharmaceuticals Surges 28% on $10 Billion AstraZeneca Takeover Bid
Key Facts
1AstraZeneca has made a roughly $10 billion offer to acquire Rhythm Pharmaceuticals.
2The potential deal aims to expand AstraZeneca's portfolio of rare disease treatments.
Rhythm Pharmaceuticals stock surged 28% following reports that AstraZeneca has made a roughly $10 billion offer to acquire the company. The Wall Street Journal reported that the potential deal aims to expand AstraZeneca's portfolio of rare disease treatments.
AZN was trading at $189.45 on November 4, 2026. Meanwhile, RYTM shares saw a sharp rally after closing at $86.44 on November 3, 2026, as AstraZeneca moves to bolster its specialized medical pipeline through targeted acquisitions.